Pharma News
08 Jun 2025 to 14 Jun 2025
Jun 14, 2025
Eli Lilly (LLY) Shares Surge Due to Impressive Drug Sales and Positive Projections for 2025
Eli Lilly (LLY) is experiencing a significant stock rally, driven by strong sales from its GLP-1 drugs Mounjaro and Zepbound, which generated $6.15 billion in Q1 2025. The stock surged 5.36% recently, with analysts projecting price targets between $800 and $1,190. Despite some valuation concerns, investor sentiment remains positive as the company expands internationally and anticipates strong revenue growth.
Jun 14, 2025
U.S. universities were responsible for patents related to half of the drugs approved by the FDA between 2020 and 2024.
A recent analysis reveals that American universities contributed patents to 50% of FDA-approved drugs from 2020 to 2024, accounting for 87% of these contributions. The study highlights the significant role of academic institutions in pharmaceutical innovation, with U.S. universities leading in breakthroughs, as tracked by the FDA’s Orange Book.
Jun 14, 2025
Merck (MRK) Achieves Significant FDA Approval for Keytruda in Treating Head and Neck Cancer
Merck (NYSE: MRK) has received FDA approval to expand the use of its leading drug, Keytruda, for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) expressing PD-L1. This approval, based on clinical studies showing a 30% reduction in cancer recurrence risk, is expected to enhance Keytruda's market position, despite Merck's shares being down 18% year-to-date.
Jun 13, 2025
Merck Receives FDA Authorization to Broaden Applications for Its Best-Selling Medication, Keytruda - Investopedia
Merck has received FDA approval to expand the use of its leading drug, Keytruda, for treating resectable locally advanced head and neck squamous cell carcinoma. Keytruda can reduce the risk of cancer recurrence, progression, or death by 30%. The drug generated over $7 billion in revenue in Q1 2023, accounting for nearly half of Merck's total sales.
Jun 13, 2025
American universities were responsible for 87% of academic patents that back FDA-approved...
A recent analysis reveals that U.S. universities contributed to 87% of academic patents supporting FDA-approved drugs from 2020 to 2024. These institutions were responsible for half of all medications approved by the FDA, highlighting their critical role in pharmaceutical innovation and research during this period.
Jun 13, 2025
BMY Concentrates on Expanding Drug Labels: Can This Stimulate Growth? - The Globe and Mail
Bristol Myers Squibb (BMY) announced that its late-stage study on Sotyktu (deucravacitinib) for active psoriatic arthritis met its primary endpoint. Sotyktu, already approved for plaque psoriasis, faces competition from Amgen’s Otezla. Additionally, the European Commission approved a subcutaneous formulation of Opdivo (nivolumab) for multiple solid tumors, although it competes with Merck’s Keytruda. BMY shares have declined 8.4% year-to-date.
Jun 13, 2025
Silently Overcoming Cancer? Struggles with Prior Authorization; FDA's Generic Drug Division Continues to Operate
A recent survey revealed that 85% of cancer patients face insurance prior authorization hurdles, causing treatment delays. BeOne Medicines received FDA approval for zanubrutinib (Brukinsa), while BioNTech acquired CureVac to advance mRNA cancer therapies. Additionally, a study found non-cancer drugs may effectively kill cancer cells, and the FDA reinstated its generic drug policy office.
Jun 13, 2025
Application for approval and permission to utilize federal rights in three patents for ...
Robert F. Kennedy, Jr. has received a request to authorize the use of federal rights in three patents for enzalutamide, marketed as Xtandi by Astellas/Pfizer, to supply generic versions to patients in government programs. The request highlights significant price disparities between the U.S. and other countries, urging action to reduce costs for Medicare and Medicaid beneficiaries.
Jun 11, 2025
Zeteo Biomedical Obtains Worldwide Patents for Its Device for Nasal and Eye Medication Delivery
Zeteo Biomedical has announced the issuance of new patents in the U.S. and EU for its drug delivery technologies, enhancing its ZTech™ platform. The patents, titled "Cartridge Devices for Administration of a Medicament" and "Hand-Operated Devices for Administration of a Medicament," focus on administering drugs and biologics through nasal, ophthalmic, and sublingual routes.
Jun 11, 2025
Kazia Therapeutics (KZIA) Soars Following Major Advancement in Breast Cancer Treatment
Kazia Therapeutics (NASDAQ: KZIA) surged 79.13% to $9.41 following promising preclinical data for its drug paxalisib in treating triple-negative breast cancer (TNBC). The study, published in Molecular Cancer Therapeutics, showed paxalisib's potential when combined with Merck's Keytruda (pembrolizumab). While the stock's momentum is strong, traders should be cautious of the inherent risks in biotech investments.
Jun 11, 2025
Comparing JNJ and MRK: Which Healthcare Giant Presents Superior Growth Opportunities? - TradingView
Johnson & Johnson (JNJ) and Merck (MRK) are both prominent U.S. pharmaceutical companies facing challenges like patent expirations and Medicare Part D redesign. JNJ's diversified portfolio and growth in its Innovative Medicine unit contrast with MRK's reliance on Keytruda. Despite headwinds, JNJ shows stronger growth prospects, while MRK struggles with declining sales in some areas. Both hold a Zacks Rank #3 (Hold).
Jun 11, 2025
Atopic Dermatitis Market Projected to Hit $22.4 Billion by 2033 Fueled by Dupixent Revenue
The atopic dermatitis market is set to reach $22.4 billion by 2033, primarily fueled by the success of Regeneron and Sanofi’s Dupixent. This blockbuster drug has transformed treatment approaches, with ongoing research promising additional therapies that will enhance patient options and further drive market growth.
Jun 11, 2025
Zeteo Biomedical has been granted new patents in the EU and US for its drug delivery innovations.
Zeteo Biomedical has secured new patents for its ZTech drug delivery technologies in the U.S. and EU, enhancing its ZTech-L and ZTech-P platforms. These innovations support metered-dose delivery for various therapeutics, including vaccines and biologics, and are designed for self-administration in diverse environments. CEO Timothy Sullivan highlighted the growing demand for compact, intuitive delivery devices.
Jun 11, 2025
Teva's Loss in the Orange Book Leads to a Reevaluation of Pharmaceutical Patent Strategies
A recent court ruling has altered the FDA's Orange Book patent listing process, impacting drug-device patents. The US Court of Appeals found that Teva Pharmaceutical Industries Ltd.'s patents for its asthma inhaler were improperly listed, as they did not name the active ingredient, albuterol sulfate. Teva plans to appeal to the Supreme Court, while patent lawyers adjust strategies to ensure compliance.
Jun 10, 2025
Insights on the Worldwide Generic Pharmaceutical Market: Trends, Growth, and Industry Analysis | - openPR.com
The global Generic Drug Market is projected to grow from USD 360.84 billion in 2022 at a CAGR of 8.4% through 2032, driven by chronic disease prevalence and patent expirations. Key players include Mylan N.V., Abbott, and Pfizer Inc. However, challenges like regulatory hurdles and price competition may impact profitability.
Jun 10, 2025
Novo Nordisk Establishes New Standard with CagriSema Obesity Study - Devdiscourse
Novo Nordisk has launched a late-stage trial for its obesity drug, CagriSema, after previous studies fell short of expectations. The trial aims to assess CagriSema's effectiveness in long-term weight loss, especially against Eli Lilly's Mounjaro. This initiative reflects Novo's strategy to enhance its position in the competitive obesity treatment market.
Jun 10, 2025
Can Merck's Keytruda Sustain Its Growth Despite Upcoming Loss of Exclusivity? - TradingView
Merck (MRK) continues to rely heavily on its blockbuster drug Keytruda, which accounts for about 50% of its sales. Despite strong growth in early-stage cancer treatments, concerns arise over Merck's dependence on Keytruda, especially with its patent expiring in 2028. The company is also developing new therapies, including a partnership with Moderna on a personalized mRNA cancer vaccine.
Jun 10, 2025
Pfizer's CEO discusses the importance of Chinese due diligence and ADC synergies to support the company's $6 billion investment in a promising bispecific treatment.
Pfizer CEO Albert Bourla announced a $1.25 billion investment in SSGJ-707, a PD-1xVEGF bispecific, emphasizing thorough due diligence on Chinese data. Despite skepticism about data from China, Bourla expressed confidence in 3SBio's credibility. Pfizer aims to leverage SSGJ-707 to enhance its antibody-drug conjugates portfolio, while remaining cautious in the obesity market due to high pricing risks.
Jun 10, 2025
Merck's promising cholesterol medication shows positive results in final phase trials - KFGO
Merck's oral cholesterol drug, enlicitide decanoate, has succeeded in two late-stage studies, showing significant reductions in LDL-C cholesterol. This non-statin treatment targets hyperlipidemia and could expand the PCSK9 market. Analysts suggest it may represent a multi-billion dollar opportunity, despite competition from AstraZeneca's AZD0780. Merck's shares rose 2% following the news.
Jun 10, 2025
American universities were responsible for 87% of the academic patents associated with drugs approved by the FDA.
A recent analysis revealed that U.S. universities contributed 87% of academic patents for FDA-approved drugs between 2020 and 2024, supporting half of all approvals. This underscores the significant role of American institutions in pharmaceutical innovation and their influence on medical advancements, as highlighted by data from the FDA’s Orange Book.
Jun 10, 2025
Analysis Report on Protein Medications for the Years 2025-2029: Therapeutic Insights - GlobeNewswire
The "Protein Drugs Market 2025" report reveals a projected growth from USD 441.7 billion in 2024 to USD 655.7 billion by 2029, with a CAGR of 8.2%. The report analyzes trends, manufacturing technologies, and competitive landscapes, featuring companies like AbbVie Inc., Bristol-Myers Squibb, and Merck & Co. It highlights the significance of therapeutic proteins in treating various diseases.
Jun 9, 2025
Patients with rare diseases are struggling due to the high prices of essential medications - The Indian Express
Seba P A, a 26-year-old from Kerala suffering from Spinal Muscular Atrophy, is advocating for affordable access to Risdiplam, a drug developed by Roche, which costs Rs 6 lakh per bottle. She has petitioned the Kerala High Court to invoke compulsory licensing to allow generic production. The case is now in the Supreme Court, highlighting the urgent need for affordable treatments for rare diseases.
Jun 9, 2025
Metsera's stock increases as early-stage trial of experimental weight-loss medication demonstrates potential.
Shares of Metsera surged 25% after its experimental weight-loss drug MET-233i demonstrated an 8.4% weight loss in a small trial. The drug, which mimics the hormone amylin, supports monthly dosing, contrasting with weekly GLP-1 drugs from Novo Nordisk and Eli Lilly. Metsera aims to capture the growing obesity drug market, currently dominated by these established players.
Jun 9, 2025
Nutriband Reveals Grant of U.S. Patent for Its Transdermal Technology Designed to Prevent Abuse
Nutriband Inc. announced the issuance of U.S. patent number 12,318,492 for its AVERSA™ transdermal abuse deterrent technology, enhancing its intellectual property protection. This technology aims to prevent the misuse of drugs like fentanyl. Nutriband's lead product, Aversa™ Fentanyl, is projected to achieve annual U.S. sales between $80 million and $200 million.
Jun 9, 2025
Glenmark receives DCGI approval to introduce Brukinsa, a blood cancer medication, in India.
Glenmark Pharmaceuticals is set to launch Zanubrutinib, branded as 'Brukinsa', in India after receiving approval from the DCGI. This oral BTK inhibitor targets five B-cell malignancies and aims to improve treatment outcomes with fewer side effects. Developed by BeOne Medicines, Brukinsa has shown promising results in clinical trials and is already approved in over 70 countries.
Jun 9, 2025
Eli Lilly optimistic about the reception of its weight-loss medication Mounjaro in India and plans for expansion.
Eli Lilly's weight-loss drug Mounjaro (tirzepatide) has received an encouraging response in India since its March launch, with sales reaching approximately Rs 23.94 crore. The company is collaborating with healthcare providers to address obesity and diabetes, emphasizing Mounjaro's clinical superiority over competitors like Novo Nordisk's Wegovy. Lilly aims to support comprehensive obesity care while navigating pricing challenges.
Jun 9, 2025
Three Generic Pharmaceutical Stocks to Monitor in Light of Pricing Challenges and Tariff Risks - TradingView
Generic drugmakers, including Sandoz (SDZNY), Teva Pharmaceuticals (TEVA), and Viatris (VTRS), face challenges from pricing competition and proposed tariffs. While branded firms benefit from exclusivity, generics struggle with tighter margins. Despite these pressures, Sandoz and Teva are well-positioned due to their diverse portfolios and biosimilars, while Viatris navigates FDA import issues. The industry remains underperforming overall.
Jun 9, 2025
Metsera's Amylin medication demonstrates promise in Phase 1 trials, indicating it could serve as a monthly treatment for obesity.
Metsera's experimental obesity drug, MET-233i, demonstrated an average 8.4% weight loss in a Phase 1 trial, positioning it competitively against GLP-1 drugs. The peptide, designed for longer-lasting effects, supports once-monthly dosing. Gastrointestinal side effects were mild and dose-dependent. Metsera also has other candidates, including MET-097i and MET-034i, in development. The company's stock rose nearly 15% following the announcement.
Jun 9, 2025
FDA grants approval for Merck's antibody treatment for RSV | BioPharma Dive
The FDA has approved Merck & Co.'s Enflonsia, an antibody treatment for infants to prevent respiratory syncytial virus (RSV). Enflonsia, which showed a 60% reduction in RSV disease incidence, aims to compete with Sanofi's Beyfortus. Unlike Beyfortus, it requires only one injection and is not weight-dependent. Shipments are expected before the 2025-2026 RSV season.
Jun 8, 2025
Eli Lilly's Mounjaro achieves Rs 24 crore in sales within three months as diabetes treatment gains popularity.
Eli Lilly’s Mounjaro (tirzepatide) has achieved nearly ₹24 crore in sales within three months of its launch in India for Type 2 diabetes and obesity. The drug, priced at ₹3,500 and ₹4,375 for its 2.5 mg and 5 mg doses, shows strong prescription growth, with expectations for increased use in the expanding obesity treatment market.
Jun 8, 2025
Sales of weight-loss medication surge as patients increase their dosage - The Economic Times
Eli Lilly's Mounjaro, a weight-loss and diabetes drug, has achieved sales of Rs 24 crore in India within three months of its launch, with a 60% month-on-month growth. The drug, available in 2.5 mg and 5 mg doses, is gaining popularity among younger patients. Experts note the need for lifestyle changes post-treatment to maintain weight loss.
